Dry AMD, Supplements and Gene Therapy: The Retina's Frontier
Anti-VEGF injections rescued the wet form of macular degeneration — the version with leaky, bleeding vessels there is a drug to block. But most macular degeneration is dry, and for a long time dry AMD had no treatment at all: no vessels to seal, no leak to plug, just a slow starving-away of the retina's most precious cells. The frontier of retinal pharmacology is everything anti-VEGF cannot fix. It runs from a humble bottle of vitamins that genuinely slows the disease, to injections that damp an ancient arm of the immune system, to a single gene threaded under the retina that can restore sight a child was born without. The direction of travel is unmistakable: away from injections every few weeks, toward durable, disease-modifying — and even genetic — cures.
An 80-year-old woman comes back to the retina clinic upset. For three years her husband had monthly injections for wet macular degeneration and kept his central vision; she has the dry form, and every visit she has been told there is "nothing to inject." On examination the centre of her macula shows a sharp-edged, pale patch where the retina has simply withered away — geographic atrophy. Her reading vision is fading around a growing blind spot, slowly, remorselessly. A few doors down sits a nine-year-old boy who has been nearly blind in dim light since birth from an inherited retinal disease; he is about to receive, once, in each eye, an injection of a working copy of the gene he was born without. Two patients at opposite ends of life, both beyond the reach of anti-VEGF — and both, for the first time, with something to offer. This is the frontier of retinal pharmacology.
Why dry AMD is a different problem
There is no leak to block, so blocking a leak is useless. Age-related macular degeneration comes in two forms, and they fail the retina by opposite mechanisms. The wet (neovascular) form — covered in the Anti-VEGF chapter — is driven by abnormal, leaky new vessels growing under the macula; block their growth factor and you switch off the leak. The dry (non-neovascular) form has no such vessels. Instead the retinal pigment epithelium (RPE) — the housekeeping cell layer that nourishes the light-sensing photoreceptors and clears their daily debris — slowly accumulates waste deposits called drusen, becomes overwhelmed, and dies. As islands of RPE die, the photoreceptors above them starve and vanish with them, leaving sharply demarcated patches of missing retina: geographic atrophy, the advanced stage of dry AMD. There is no leak here, no vessel, nothing to plug. Anti-VEGF does nothing. The disease is a slow degeneration, and it demands a completely different pharmacology.
The vitamin bottle that actually works
Walk into any pharmacy and the shelves groan with "eye health" supplements, almost all of them marketing. One is different, because it was tested in large randomised trials and it genuinely works: the AREDS formula, from the Age-Related Eye Disease Study. In people with intermediate AMD, a specific combination of antioxidant vitamins C and E, plus the minerals zinc and copper, and the macular carotenoids lutein and zeaxanthin, reduces the risk that intermediate AMD progresses to advanced, sight-threatening disease by roughly a quarter. The logic is a defence against oxidative stress: the macula is the most metabolically intense, most light-battered patch of tissue in the body, and these nutrients bolster its antioxidant defences and rebuild the pigment that filters damaging blue light. This is one of the very few places in medicine where a nutritional supplement is genuine, evidence-based therapy — and it connects directly to the future Vitamins & Nutrition topic, where the same antioxidant and trace-mineral biology is taught in full.
The most important refinement came from a harm, not a benefit. The original AREDS formula used beta-carotene as its main antioxidant. Then a signal emerged that will stay with you: in current and former smokers, high-dose beta-carotene raised the risk of lung cancer. So the follow-up study, AREDS2, swapped beta-carotene out and put lutein and zeaxanthin in its place — carotenoids native to the macula itself, with equal ocular benefit and no lung-cancer signal. That is why the modern formula deliberately contains no beta-carotene. It is a clean example of a recurring pharmacology lesson: a supplement is still a drug, dose matters, and "natural" is not the same as "harmless" — especially in a smoker.
Think of the macula as a solar panel running at full output all day, every day. Sunlight is exactly what it is built to catch — and exactly what corrodes it. The RPE beneath is the maintenance crew, wiping the panel clean and hauling away the scorched residue each night. In dry AMD the crew ages, the residue piles up as drusen, and eventually the crew itself dies; wherever it does, that square of panel goes permanently dark. The AREDS supplement is not a repair — it is better rust-proofing and a darker anti-glare coating, slowing the corrosion so more of the panel survives longer.
- Dry (non-neovascular) AMD has no leaky vessels — anti-VEGF does nothing for it.
- It is a degeneration: RPE cells overwhelmed by drusen die, and photoreceptors starve above them.
- Geographic atrophy is the advanced stage — sharp patches of missing retina and central vision.
- The AREDS2 formula (vitamins C + E, zinc, copper, lutein, zeaxanthin) slows intermediate→advanced AMD.
- Beta-carotene was removed because it raised lung-cancer risk in smokers.
- AREDS is one of medicine's few genuinely evidence-based nutritional therapies.
Complement inhibitors: injecting for the dry form
The newest drugs target an ancient arm of the immune system. For decades "nothing to inject" was the truth of geographic atrophy. That has just changed. Genetics pointed the way: many of the strongest risk genes for AMD lie in the complement system — the cascade of blood proteins that tags and destroys debris and microbes. In AMD this cascade appears chronically over-activated at the macula, and its terminal machinery helps drive the death of RPE and photoreceptors. So the new strategy is to dampen it locally. Two intravitreal drugs are now approved for geographic atrophy: pegcetacoplan, which blocks complement protein C3 (high in the cascade, so it damps everything downstream), and avacincaptad pegol, which blocks C5 (lower down, nearer the final membrane-attack step). Injected into the vitreous every one to two months, they do not restore lost retina — they slow the enlargement of the atrophic patch, buying time before the blind area reaches the very centre of vision.
Notice the honesty demanded of both drug and doctor here. A complement inhibitor for geographic atrophy does not make anyone see better — it slows the rate at which they will see worse. That is a harder conversation than wet AMD, where anti-VEGF can visibly rescue vision. The realistic promise is "a slower decline," and the patient must accept an injection every month or two, indefinitely, for a benefit they will never actually feel — only, in the long run, fail to lose. Weighing that trade-off honestly is the clinical skill this whole class demands.
The complement idea is not confined to the eye. The same cascade — C3 and C5 — is the target of systemic drugs in blood and kidney disorders (the anti-C5 antibody eculizumab in paroxysmal nocturnal haemoglobinuria is the classic example), which is why this section rhymes so closely with the Inflammation & Immunity chapter. What is distinctive in the eye is the route: rather than block complement throughout the bloodstream — where it is needed to fight infection — the drug is delivered straight into the enclosed vitreous, damping the cascade only where the disease lives. It is the same logic of local delivery that runs through all of ocular pharmacology, and it is only possible because the eye is a sealed compartment.
Gene therapy: fixing the instruction, not the symptom
Some retinal diseases are a single broken gene — so replace it. The deepest shift on this frontier is from treating symptoms to correcting the underlying instruction. A group of inherited retinal dystrophies are caused by a single faulty gene: the photoreceptors or RPE lack one working protein and slowly degenerate. The landmark is voretigene neparvovec (Luxturna), the first gene therapy ever approved for an inherited disease of any kind. It treats retinal dystrophy caused by mutations in the RPE65 gene — a cause of Leber congenital amaurosis, a severe childhood blindness. RPE65 encodes an enzyme the RPE needs to regenerate the light-sensitive pigment; without it the retina is starved of usable visual pigment and vision, especially in dim light, fails from birth. The therapy delivers a healthy copy of RPE65 packaged inside a harmless adeno-associated virus (AAV), which acts as a molecular courier: it is injected subretinally — surgically, into the space between the retina and the RPE — so the virus can hand the working gene directly to the cells that need it. The RPE starts making the missing enzyme, and children treated early can navigate a dimly lit room for the first time.
Of all the organs in the body, the eye is the one gene therapy was made for. Why did the first approved gene therapy target the eye rather than the liver or the heart? Because the eye is an almost perfect gene-therapy target, for the very reasons set out in the Foundations chapter on the eye as a drug target. It is small, so a tiny dose of vector reaches a large fraction of the relevant cells. It is enclosed and compartmentalised, so the virus stays where it is placed and does not wash into the rest of the body. It is immune-privileged — the same blood–ocular barriers and immune tolerance that protect the eye also blunt the immune reaction that would otherwise attack a viral vector. It is directly visible and testable, so the effect can be watched and measured non-invasively. And the two eyes offer a built-in control. Every property that makes drug delivery to the eye a puzzle in the first place is exactly what makes it the ideal proving ground for genetic medicine.
Dry AMD, slow progression: AREDS2 supplement (vitamins C + E, zinc, copper, lutein, zeaxanthin — no beta-carotene). Geographic atrophy, slow the atrophy: intravitreal complement inhibitors — pegcetacoplan (anti-C3), avacincaptad pegol (anti-C5). Inherited RPE65 retinopathy / Leber congenital amaurosis: subretinal AAV gene therapy — voretigene neparvovec (Luxturna). In the pipeline: gene therapies for choroideremia and X-linked retinitis pigmentosa; longer-acting anti-VEGF delivery — the refillable port-delivery system implanted in the eye wall — to cut the injection burden of wet AMD; and neuroprotection strategies that aim to keep photoreceptors and retinal ganglion cells alive whatever the original insult.
- Complement inhibitors (pegcetacoplan anti-C3, avacincaptad pegol anti-C5) are intravitreal drugs for geographic atrophy.
- They slow the growth of atrophy — they do not restore vision that is already lost.
- Voretigene neparvovec (Luxturna) was the first approved gene therapy: an AAV delivering a working RPE65 gene, injected subretinally.
- The eye is an ideal gene-therapy target: small, enclosed, immune-privileged, and directly observable.
- Emerging: gene therapy for choroideremia and X-linked RP, and refillable port-delivery anti-VEGF to cut injections.
- The arc: from repeated injections toward durable, disease-modifying and genetic cures.
- Offering anti-VEGF for dry AMD or geographic atrophy — there is no leaky vessel to block; anti-VEGF has no role in the non-neovascular form.
- Recommending the old beta-carotene AREDS formula to a smoker — beta-carotene raised lung-cancer risk, and AREDS2 replaced it with lutein/zeaxanthin.
- Promising that complement inhibitors or gene therapy will improve current vision — complement drugs only slow decline, and gene therapy rescues cells that are still alive, not ones already lost.
A 79-year-old former smoker with intermediate dry AMD in both eyes asks what he can do to protect his vision. Which recommendation is most appropriate?
- Dry (non-neovascular) AMD has no leaky vessels, so anti-VEGF is useless; it is a degeneration of the RPE that ends in geographic atrophy.
- The AREDS2 supplement (vitamins C + E, zinc, copper, lutein, zeaxanthin — beta-carotene removed for smokers) slows intermediate AMD to advanced disease.
- New intravitreal complement inhibitors — pegcetacoplan (anti-C3) and avacincaptad pegol (anti-C5) — slow geographic-atrophy growth by damping the complement cascade.
- Voretigene neparvovec (Luxturna) — subretinal AAV gene therapy for RPE65 disease — was the first ocular gene therapy; the eye's small, enclosed, immune-privileged nature makes it the ideal target, and the field is moving toward durable, genetic cures.
- Age-Related Eye Disease Study Research Group (AREDS Report No. 8) and AREDS2 Research Group. JAMA / JAMA Ophthalmology.
- Kanski's Clinical Ophthalmology — Acquired macular disorders: age-related macular degeneration.
- AAO Basic and Clinical Science Course (BCSC), Section 12: Retina and Vitreous.
- Liao DS, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy (FILLY / OAKS-DERBY programme).
- Russell S, et al. Voretigene neparvovec for RPE65-mediated inherited retinal dystrophy. The Lancet.
- Bartlett & Jaanus, Clinical Ocular Pharmacology — Retinal pharmacotherapeutics and emerging therapies.
